Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 18/20 | 0.46 |
| ▸ | HTR2B | P41595 | 17/20 | 0.46 |
| ▸ | HTR2A | P28223 | 14/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | FABP6 | P51161 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4410961 | 0.99 | HTR2C (0.45) | HTR2CHTR2BHTR2AAXLFABP6 | |
| SCHEMBL13595228 | 0.85 | HTR2C (0.64) | HTR2CHTR2BHTR2AAXL | |
| SCHEMBL13595218 | 0.85 | HTR2C (0.64) | HTR2CHTR2BHTR2AAXL | |
| SCHEMBL13595225 | 0.85 | HTR2C (0.46) | HTR2CHTR2BHTR2AAXL | |
| SCHEMBL13595220 | 0.84 | HTR2C (0.66) | HTR2CHTR2BHTR2AAXL | |
| Hydrochloric Acid SCHEMBL4410966 | 0.84 | HTR2C (0.62) | HTR2CHTR2BHTR2AAXL | |
| Hydrochloric Acid SCHEMBL4407112 | 0.84 | HTR2C (0.45) | HTR2CHTR2BHTR2AAXL | |
| Hydrochloric Acid SCHEMBL4408050 | 0.84 | HTR2C (0.62) | HTR2CHTR2BHTR2AAXL | |
| Hydrochloric Acid SCHEMBL4408432 | 0.83 | HTR2C (0.65) | HTR2CHTR2BHTR2AAXL | |
| SCHEMBL13595236 | 0.82 | HTR2C (0.49) | HTR2CHTR2BHTR2AAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 9/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.